세계의 Drug Discovery 서비스 시장 : 시장 규모 및 점유율 분석 - 프로세스별, 종류별, 의약품 유형별, 치료 영역별, 최종사용자별 - 산업 수요 예측(-2030년)
Drug Discovery Services Market Size and Share Analysis by Process, Type, Drug Type, Therapeutic Area, End User - Global Industry Demand Forecast to 2030
시장 개요
세계의 Drug Discovery 서비스 시장 규모는 2023년에 210억 달러로 추산되며, 2030년에는 542억 달러에 달할 것으로 예측되고 있습니다. 또한 2024-2030년 CAGR은 14.7%에 상당합니다.
바이오의약품 업계 및 제약 업계에서 연구개발 투자의 증가, 분석 시험 시설의 아웃소싱 요구의 증가, 희소 의약품 및 희귀질환 연구 스텝, 자사에서의 의약품 개발에는 비용이 드는 것 등이 세계의 업계에서 새로운 매출의 문을 열고 있습니다.
주요 인사이트
2023년, Drug Discovery 서비스 업계에서는 히트·투·리드 식별 카테고리가 35%의 최대 점유율을 차지했습니다.
2023년에는 화학 카테고리가 시장에서 60%의 최고 점유율을 차지하고 있습니다.
저분자 의약품 카테고리는 업계에서 큰 점유율을 차지하고 있으며, 세계의 신규 치료법의 출현에 필수적입니다. 저분자 의약품은 특수 의약품 판매의 50%를 차지하며 2020년 FDA 승인의 75% 이상을 차지하고 있습니다.
북미 지역은 최근 의약품 개발 서비스에서 55%라는 최대 업계 점유율을 차지하고 있습니다.
세계의 Drug Discovery 서비스 시장을 분석했으며, 시장의 기본 구조·최신 상황 및 주요 촉진·억제요인, 세계 전체 및 지역별·주요 국가 시장 규모의 동향 전망(금액 기반, 2017-2030년), 프로세스별·종류별·의약품 유형별·치료 영역별·최종사용자별의 상세 동향, 현재의 시장 경쟁 상황, 주요 기업의 개요 등을 조사하여 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계의 전망
- 시장 역학
- 동향
- 촉진요인
- 억제요인/과제
- 촉진요인/억제요인의 영향 분석
- 신종 코로나바이러스 감염증(COVID-19)의 영향
- Porter's Five Forces 분석
제6장 세계 시장
- 개요
- 시장 매출 : 프로세스별(2017-2030년)
- 시장 매출 : 종류별(2017-2030년)
- 시장 매출 : 의약품 유형별(2017-2030년)
- 시장 매출 : 치료 영역별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 프로세스별(2017-2030년)
- 시장 매출 : 종류별(2017-2030년)
- 시장 매출 : 의약품 유형별(2017-2030년)
- 시장 매출 : 치료 영역별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카 시장
제12장 미국 시장
- 개요
- 시장 매출 : 프로세스별(2017-2030년)
- 시장 매출 : 종류별(2017-2030년)
- 시장 매출 : 의약품 유형별(2017-2030년)
- 시장 매출 : 치료 영역별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카공화국 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 참여 기업과 제공 제품/서비스 리스트
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근 전략 개발 상황
제30장 기업 개요
- Charles River Laboratories International Inc.
- Eurofins Scientific Limited
- Frontage Laboratories Inc.
- Galapagos NV
- General Electric
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific Inc.
- Syngene International Limited
- WuXi AppTec
제31장 부록
KSA
Market Overview
In 2023, the estimated value of the global drug discovery services market is USD 21.0 billion, projected to reach USD 54.2 billion by 2030. This growth represents a Compound Annual Growth Rate of 14.7% during the period from 2024 to 2030.
The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.
One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.
On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.
Key Insights
In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.
This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.
Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.
High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.
Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.
In 2023, the chemistry category grips a leading share of 60% in the market.
Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.
The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.
Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.
Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.
Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.
They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.
The North American region holds the largest industry share of 55% in the recent years in drug advancement services.
The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.
Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.
Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by process
- 1.4.2. Market size breakdown, by type
- 1.4.3. Market size breakdown, by drug type
- 1.4.4. Market size breakdown, by therapeutic area
- 1.4.5. Market size breakdown, by end user
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Process (2017-2030)
- 6.3. Market Revenue, by Type (2017-2030)
- 6.4. Market Revenue, by Drug Type (2017-2030)
- 6.5. Market Revenue, by Therapeutic Area (2017-2030)
- 6.6. Market Revenue, by End User (2017-2030)
- 6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Process (2017-2030)
- 7.3. Market Revenue, by Type (2017-2030)
- 7.4. Market Revenue, by Drug Type (2017-2030)
- 7.5. Market Revenue, by Therapeutic Area (2017-2030)
- 7.6. Market Revenue, by End User (2017-2030)
- 7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Process (2017-2030)
- 8.3. Market Revenue, by Type (2017-2030)
- 8.4. Market Revenue, by Drug Type (2017-2030)
- 8.5. Market Revenue, by Therapeutic Area (2017-2030)
- 8.6. Market Revenue, by End User (2017-2030)
- 8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Process (2017-2030)
- 9.3. Market Revenue, by Type (2017-2030)
- 9.4. Market Revenue, by Drug Type (2017-2030)
- 9.5. Market Revenue, by Therapeutic Area (2017-2030)
- 9.6. Market Revenue, by End User (2017-2030)
- 9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Process (2017-2030)
- 10.3. Market Revenue, by Type (2017-2030)
- 10.4. Market Revenue, by Drug Type (2017-2030)
- 10.5. Market Revenue, by Therapeutic Area (2017-2030)
- 10.6. Market Revenue, by End User (2017-2030)
- 10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Process (2017-2030)
- 11.3. Market Revenue, by Type (2017-2030)
- 11.4. Market Revenue, by Drug Type (2017-2030)
- 11.5. Market Revenue, by Therapeutic Area (2017-2030)
- 11.6. Market Revenue, by End User (2017-2030)
- 11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Process (2017-2030)
- 12.3. Market Revenue, by Type (2017-2030)
- 12.4. Market Revenue, by Drug Type (2017-2030)
- 12.5. Market Revenue, by Therapeutic Area (2017-2030)
- 12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Process (2017-2030)
- 13.3. Market Revenue, by Type (2017-2030)
- 13.4. Market Revenue, by Drug Type (2017-2030)
- 13.5. Market Revenue, by Therapeutic Area (2017-2030)
- 13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Process (2017-2030)
- 14.3. Market Revenue, by Type (2017-2030)
- 14.4. Market Revenue, by Drug Type (2017-2030)
- 14.5. Market Revenue, by Therapeutic Area (2017-2030)
- 14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Process (2017-2030)
- 15.3. Market Revenue, by Type (2017-2030)
- 15.4. Market Revenue, by Drug Type (2017-2030)
- 15.5. Market Revenue, by Therapeutic Area (2017-2030)
- 15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Process (2017-2030)
- 16.3. Market Revenue, by Type (2017-2030)
- 16.4. Market Revenue, by Drug Type (2017-2030)
- 16.5. Market Revenue, by Therapeutic Area (2017-2030)
- 16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Process (2017-2030)
- 17.3. Market Revenue, by Type (2017-2030)
- 17.4. Market Revenue, by Drug Type (2017-2030)
- 17.5. Market Revenue, by Therapeutic Area (2017-2030)
- 17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Process (2017-2030)
- 18.3. Market Revenue, by Type (2017-2030)
- 18.4. Market Revenue, by Drug Type (2017-2030)
- 18.5. Market Revenue, by Therapeutic Area (2017-2030)
- 18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Process (2017-2030)
- 19.3. Market Revenue, by Type (2017-2030)
- 19.4. Market Revenue, by Drug Type (2017-2030)
- 19.5. Market Revenue, by Therapeutic Area (2017-2030)
- 19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Process (2017-2030)
- 20.3. Market Revenue, by Type (2017-2030)
- 20.4. Market Revenue, by Drug Type (2017-2030)
- 20.5. Market Revenue, by Therapeutic Area (2017-2030)
- 20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Process (2017-2030)
- 21.3. Market Revenue, by Type (2017-2030)
- 21.4. Market Revenue, by Drug Type (2017-2030)
- 21.5. Market Revenue, by Therapeutic Area (2017-2030)
- 21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Process (2017-2030)
- 22.3. Market Revenue, by Type (2017-2030)
- 22.4. Market Revenue, by Drug Type (2017-2030)
- 22.5. Market Revenue, by Therapeutic Area (2017-2030)
- 22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Process (2017-2030)
- 23.3. Market Revenue, by Type (2017-2030)
- 23.4. Market Revenue, by Drug Type (2017-2030)
- 23.5. Market Revenue, by Therapeutic Area (2017-2030)
- 23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Process (2017-2030)
- 24.3. Market Revenue, by Type (2017-2030)
- 24.4. Market Revenue, by Drug Type (2017-2030)
- 24.5. Market Revenue, by Therapeutic Area (2017-2030)
- 24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Process (2017-2030)
- 25.3. Market Revenue, by Type (2017-2030)
- 25.4. Market Revenue, by Drug Type (2017-2030)
- 25.5. Market Revenue, by Therapeutic Area (2017-2030)
- 25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Process (2017-2030)
- 26.3. Market Revenue, by Type (2017-2030)
- 26.4. Market Revenue, by Drug Type (2017-2030)
- 26.5. Market Revenue, by Therapeutic Area (2017-2030)
- 26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Process (2017-2030)
- 27.3. Market Revenue, by Type (2017-2030)
- 27.4. Market Revenue, by Drug Type (2017-2030)
- 27.5. Market Revenue, by Therapeutic Area (2017-2030)
- 27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Process (2017-2030)
- 28.3. Market Revenue, by Type (2017-2030)
- 28.4. Market Revenue, by Drug Type (2017-2030)
- 28.5. Market Revenue, by Therapeutic Area (2017-2030)
- 28.6. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Charles River Laboratories International Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Eurofins Scientific Limited
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Frontage Laboratories Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Galapagos NV
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. General Electric
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Laboratory Corporation of America Holdings
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Thermo Fisher Scientific Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Syngene International Limited
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. WuXi AppTec
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
